Switch theme
Sign up to access all valuation multiples
Hybio Pharmaceutical Co Ltd is engaged in manufacturing and sale of peptide products. The company's peptide finished dosage products include digestive system agents, immune modulators, hormone and endocrine modulators, antiviral agents, and hemostatic products. It also provides peptide CRO and CMO services, as well as API products.
2003
n/a
Last FY Revenue $82.4M
Last FY EBITDA $12.9M
$2.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Hybio Pharmaceutical achieved revenue of $82.4M and an EBITDA of $12.9M.
Hybio Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Hybio Pharmaceutical valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $82.4M | XXX | XXX | XXX |
| Gross Profit | XXX | $47.0M | XXX | XXX | XXX |
| Gross Margin | XXX | 57% | XXX | XXX | XXX |
| EBITDA | XXX | $12.9M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 16% | XXX | XXX | XXX |
| EBIT | XXX | $2.9M | XXX | XXX | XXX |
| EBIT Margin | XXX | 4% | XXX | XXX | XXX |
| Net Profit | XXX | -$24.2M | XXX | XXX | XXX |
| Net Margin | XXX | -29% | XXX | XXX | XXX |
| Net Debt | XXX | $196M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 16, 2025, Hybio Pharmaceutical's stock price is CNY 18 (or $3).
Hybio Pharmaceutical has current market cap of CNY 16.1B (or $2.3B), and EV of CNY 17.8B (or $2.5B).
See Hybio Pharmaceutical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.5B | $2.3B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 16, 2025, Hybio Pharmaceutical has market cap of $2.3B and EV of $2.5B.
Hybio Pharmaceutical's trades at 30.2x EV/Revenue multiple, and 193.2x EV/EBITDA.
Equity research analysts estimate Hybio Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Hybio Pharmaceutical's P/E ratio is not available.
See valuation multiples for Hybio Pharmaceutical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.3B | XXX | $2.3B | XXX | XXX | XXX |
| EV (current) | $2.5B | XXX | $2.5B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 30.2x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 193.2x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 853.6x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -92.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 365.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialHybio Pharmaceutical's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Hybio Pharmaceutical's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Hybio Pharmaceutical's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Hybio Pharmaceutical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 16% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 17% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 15% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 54% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cohance Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Hybio Pharmaceutical acquired XXX companies to date.
Last acquisition by Hybio Pharmaceutical was XXXXXXXX, XXXXX XXXXX XXXXXX . Hybio Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Hybio Pharmaceutical founded? | Hybio Pharmaceutical was founded in 2003. |
| Where is Hybio Pharmaceutical headquartered? | Hybio Pharmaceutical is headquartered in China. |
| Who is the CEO of Hybio Pharmaceutical? | Hybio Pharmaceutical's CEO is Ms. Yu Pinxiang. |
| Is Hybio Pharmaceutical publicy listed? | Yes, Hybio Pharmaceutical is a public company listed on SHE. |
| What is the stock symbol of Hybio Pharmaceutical? | Hybio Pharmaceutical trades under 300199 ticker. |
| When did Hybio Pharmaceutical go public? | Hybio Pharmaceutical went public in 2011. |
| Who are competitors of Hybio Pharmaceutical? | Similar companies to Hybio Pharmaceutical include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of Hybio Pharmaceutical? | Hybio Pharmaceutical's current market cap is $2.3B |
| Is Hybio Pharmaceutical profitable? | Yes, Hybio Pharmaceutical is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
